fig7
Figure 7. Val-miR218 reduces tumor weight and tumor volume in vivo. Xenografts were treated intratumorally with 0.75 mg/kg of val-miR218 twice weekly. The application was given in a total of 9 times. (A) Tumor volume was measured every 3 days. (B) and (C) Tumor volume and tumor weight were determined one day after the last injection. Compared to control group, *P<0.05, **P<0.01, ***P<0.001.
